Compare Adaptive Biotechnologies Corp (ADPT) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs KLA Corp. — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while KLA Corp. trades at $204.94 (market cap $261.92B). The key difference: KLA Corp. is far larger — about 64.8× Adaptive Biotechnologies Corp's market cap, and KLA Corp. pays a 0.46% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | KLAC | |
|---|---|---|
Market Cap | $4.04B | $261.92B |
Sector | Health | Technology |
52-Week High | $25.45 | $301.71 |
52-Week Low | $12.30 | $84.39 |
Enterprise Value | $4.10B | $263.17B |
Dividend Yield | — | 0.46% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
